Excessive Reverse Payments in the Context of Hatch-Waxman

Download Full Text PDF

Volume 10, Issue 2 (Jun 2012)

Reverse payments, such as the one at issue in Arkansas Carpenters Health & Welfare Fund v. Bayer AG, are controversial because they appear to be nothing more than agreements between competitors not to compete. However, because a patent was involved, the Federal Circuit refused to declare this agreement unlawful—even when the patentee offered to pay the alleged infringer large sums of money to exit the market. The recent introduction of The Preserve Access to Affordable Generics Act is an attempt by Congress to clarify its intent with respect to reverse payments under Hatch-Waxman. Although this legislation targets the right problem, it is too broad a solution because it would prohibit pro-competitive settlements in some circumstances. This Recent Development suggests modifying the Act so that such settlements would be prohibited only where the underlying patent is likely invalid or not infringed.

Satish Chintapalli, Recent Development, Excessive Reverse Payments in the Context of Hatch-Waxman, 10 N.C. J.L. & Tech. 381 (2009), available at http://ncjolt.org/wp-content/uploads/2016/09/14_10NCJLTech3812008-2009.pdf.

The North Carolina Journal of Law & Technology has adopted the Open Access Program, a part of the Scholar’s Copyright Project created by Science Commons. Authors designate the conditions under which their articles are licensed. By downloading articles, you agree to comply with the license terms specified. Please contact NC JOLT at eic.ncjolt@gmail.com with permissions inquiries.